The KDOQI Work Group and Dr. Michelle L. Robbin from the University of Alabama at Birmingham, offer valuable guidelines for successful hemodialysis cannulation of fistulas in end-stage-renal-disease (ESRD) patients. It is recommended that a 4 mm or greater vessel diameter and flow of 500 mL/min or greater is needed to support successful hd cannulation and dialysis blood flow rates. Ultrasound is not needed for cannulation. Also suggested is the following Rule of Sixes:
Dr. Lymaris GarcÌa-Medina and colleagues from the Universitario Reina Sofia General Hospital in Murcia, Spain analyzed the flow values measured by the Transonic ReoCath® Flow Catheter to determine whether the ReoCath’s measurements were more reliable than angiographic and clinical findings for planning and determining the outcome of invasive radiologic treatments of hemodialysis fistulas.
The success of percutaneous transluminal angioplasty (PTA) in stenotic hemodialysis prosthetic grafts and autogenous fistulas is traditionally assessed by the post-intervention vessel diameter of the grafts or fistulas. Interventionalists at the University of San Diego sought to compare this traditional measure of success (vessel diameter), and pre- and post-intervention real-time intra-access blood flow rates with access blood flow measured during hemodialysis.
Topics: Blood Flow Measurement
NKF-KDOQI guidelines recommend that the vascular access flow assessment be performed during the first 90 minutes of hemodialysis to eliminate error caused by decrease in cardiac output or blood pressure related to ultrafiltration and/or hypotension. This measurement time restriction to within the first 90 minutes limits the number of measurements that can be performed by one operator, which is a significant issue in clinical practice.
Children undergoing hemodialysis present unique challenges for dialysis providers. Hemodialysis in children presents challenges: Little is known about their ideal vein and artery sizes, maturation times and expected volume flow rates to achieve a functioning fistula.
After clinicians at London’s Great Ormond Street Hospital for Children reviewed the outcomes of 25 children who received an arteriovenous fistula (AVF), they found that five had primary AVF failure, and three had secondary AVF failure.
Two of the most common options for treating a vascular access stenosis in hemodialysis patients are percutaneous transluminal angioplasty (PTA) and fistula reconstruction/revision surgery. Because it is more convenient, PTA has become preferable to surgical revision.
To examine the efficacy of and compare percutaneous transluminal angioplasty or surgical repair, clinicians from three hospitals in Taiwan investigated the duration of fistulas and maintenance costs for dialysis patients. Their study was published in the 2017 February issue of the Journal of Vascular Access.
In the study, charts were reviewed retrospectively from 544 hemodialysis patients from two dialysis units in a teaching hospital in the southern area of Taiwan. Researchers analyzed the frequency of PTA or revascularization surgery and the use of related medical resources.
It only takes minutes to save your hemodialysis access, your lifeline. All you have to do is look, listen, feel and then also measure.
DaVita Appoints Robert Lang President of International Market
Before joining DaVita, Lang led the international markets business at insurance provider Bupa. He has experience working in Europe, the Middle East, Asia and Latin America.
Do Dialysis Patients Feel Safe?
According to data from the 2007 Renal Physicians Association (RPA) Health and Safety Survey Project, nearly half of dialysis patients surveyed said they “sometimes, usually or always worry that someone will make a medical mistake during one of their dialysis treatments.” Not only that, 87 percent of staff indicated a mistake had been made in a patient’s treatment over the last three months.
Ashfaq Named Senior VP of OPKO Health Renal Division
Dr. Akhtar Ashfaq has been named senior vice president of clinical research and development of OPKO Health’s renal division. He will support the adoption of Rayaldee extended-release capsules by healthcare professionals caring for patients with stage 3 or 4 kidney disease.
He’ll also lead the development of the drug to treat secondary hyperparathyroidism (SHPT) in adults on hemodialysis with vitamin D insufficiency as well as the development of Alpharen for the treatment of hyperphosphatemia in adults with stage 5 kidney disease.
Source: Nephrology News & Issues
Topics: kidney care